Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
The Penumbra thrombectomy pulmonary embolism clots extraction catheter displayed at TCT 2025. Photo by Dave Fornell

Pulmonary embolism thrombectomy use increases by more than 700%

Medicare claims submitted between 2017 and 2022 showed a 712% increase in thrombectomy for pulmonary embolism (PE) and a 137% increase in thrombectomy for deep vein thrombosis (DVT).

Well-known cardiologist Peter A. Soukas, MD, FACC, FSCAI, FSVM, FACP, has become chief medical officer of carotid stent maker InspireMD Inc.

Cardiologist Peter Soukas becomes chief medical officer of carotid stent company

The company said the move will help it prepare for what is expected to be a rapid expansion of carotid stenting.

Contractor for clinician-focused addiction recovery program sued over ‘punishingly expensive’ practices

The plaintiffs, 10 nurses and one doctor, are all enrolled in the state-mandated initiative for clinicians with past substance abuse issues. The rules require monitoring and regular drug testing to prove sobriety; however, the lot argues that the contractor in charge, Maximus, is being dishonestly punitive.

phenylephrine FDA

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

How to minimize bleeding risks after TAVR

Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.

rope pulling tug of war bidding war

Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly

Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.

stock market IPO

Private equity-backed Medline files for IPO

The company, founded in 1966, has been providing supplies to cardiac surgery suites and cath labs for decades.

Hadley Wilson, MD, MACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, shares what he felt were the most important clinical trials presented at the TCT 2025.

Key takeaways for interventional cardiology from TCT 2025

B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.

Displaying 65 - 72 of 6861
Design by Adaptive Theme